Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leukemia risk factor ARID5B coordinates HDAC-mediated transcriptional repression.

Nucleic acids research·2026
Same author

Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition.

Molecular therapy. Oncology·2026
Same author

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.

Cancer medicine·2026
Same author

Disruption of the SAGA CORE triggers collateral degradation of KAT2A.

Nature communications·2026
Same author

Differential immune infiltrates in histomorphologic Wilms tumor regions identify prognostic macrophages.

Molecular therapy. Oncology·2026
Same author

The unphosphorylated, closed form of ezrin binds to RNA to maintain a metastatic phenotype in osteosarcoma cells.

Science signaling·2026
Same journal

Editor's Note: Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-like Growth Factor I Receptor Monoclonal Antibody.

Molecular cancer therapeutics·2026
Same journal

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

Molecular cancer therapeutics·2026
Same journal

RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model.

Molecular cancer therapeutics·2026
Same journal

Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib.

Molecular cancer therapeutics·2026
Same journal

Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.

Molecular cancer therapeutics·2026
Same journal

Concurrent inhibition of ICMT and RAF/MEK suppresses RAC1P29S-driven MAPK-pathway-inhibitor resistance in BRAFV600E melanoma by regulating TAZ activity.

Molecular cancer therapeutics·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.

Branka Radic-Sarikas1, Kalliopi P Tsafou2,3, Kristina B Emdal4

  • 1CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Molecular Cancer Therapeutics
|January 8, 2017
PubMed
Summary
This summary is machine-generated.

New drug combinations show promise for treating Ewing sarcoma, a rare pediatric cancer. Researchers identified synergistic drug pairings that target specific cancer cell pathways, potentially improving survival rates for young patients.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

13.0K

Related Experiment Videos

Last Updated: Mar 9, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

13.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Survival rates for pediatric and adolescent Ewing sarcoma patients have seen limited improvement over two decades.
  • Anticancer drug combinations are explored to overcome treatment resistance and reduce adverse effects via lower doses, crucial for childhood cancers.

Purpose of the Study:

  • To identify Ewing sarcoma-specific synergistic drug combinations using a phenotypic screening approach.
  • To elucidate the molecular mechanisms underlying the synergistic effects of targeted agents in Ewing sarcoma.

Main Methods:

  • Utilized a parallel phenotypic combinatorial screening of cells from three pediatric tumor types.
  • Generated a molecular target profile of PKC412 and analyzed synergistic effects with IGF1R inhibitors using quantitative phosphoproteomics.

Main Results:

  • Identified highly synergistic drug combinations specifically for Ewing sarcoma, targeting EWS-FLI1-dependent signaling pathways.
  • Uncovered a novel synergistic mechanism between PKC412 and IGF1R inhibitors that inhibits pathway crosstalk and feedback loops.

Conclusions:

  • Synergistic drug combinations, particularly PKC412 and IGF1R inhibitors, offer a promising strategy for Ewing sarcoma treatment.
  • The identified molecular mechanisms provide a basis for developing more effective targeted therapies for this pediatric cancer.